Celldex Therapeutics, based in the United States, is a pharmaceutical company specializing in immunotherapy and cancer-targeting biologics. With a Risk Rating Score of 24.5, the company is considered to have a medium risk. Celldex Therapeutics is actively involved in clinical trials for various types of cancer, including breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. The company's pipeline products, such as Varlilumab and CDX-301, are at the forefront of cutting-edge ESG technologies in the pharmaceutical industry.